Taher Abbasi

Learn More
Glioblastoma (GBM) is a therapeutic challenge, associated with high mortality. More effective GBM therapeutic options are urgently needed. Hence, we screened a large multi-class drug panel comprising the NIH clinical collection (NCC) that includes 446 FDA-approved drugs, with the goal of identifying new GBM therapeutics for rapid entry into clinical trials(More)
BACKGROUND The increasing usage of statins (the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) has revealed a number of unexpected beneficial effects, including a reduction in cancer risk. METHODS We investigated the direct anticancer effects of different statins approved for clinical use on human breast and brain cancer cells. We also(More)
Introduction Ursolic acid (UA) is a pentacyclic triterpene acid present in many plants, including apples, basil, cranberries, and rosemary. UA suppresses proliferation and induces apoptosis in a variety of tumor cells via inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB). Given that single agent therapy is a major clinical(More)
Glioblastoma (GBM) is an aggressive disease associated with poor survival. It is essential to account for the complexity of GBM biology to improve diagnostic and therapeutic strategies. This complexity is best represented by the increasing amounts of profiling (“omics”) data available due to advances in biotechnology. The challenge of integrating these vast(More)
The personalization of cancer treatments implies the reconsideration of a one-size-fits-all paradigm. This move has spawned increased use of next generation sequencing to understand mutations and copy number aberrations in cancer cells. Initial personalization successes have been primarily driven by drugs targeting one patient-specific oncogene (e.g.,(More)
Correction After publishing this article [1], we noted mistake in the spelling of co-author Rajesh Mukthavaram's names. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. Cite this article as: Jiang et al.: Correction: novel anti-glioblastoma agents and therapeutic combinations identified from a(More)
Correction After publishing this article [1], we noted mistake in the spelling of co-author Rajesh Mukthavaram's names. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. Cite this article as: Jiang et al.: Correction: novel anti-glioblastoma agents and therapeutic combinations identified from a(More)
  • 1